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pump (IABP). Their survival to hospital discharge is
reported to be around 50%.1,2 At this moment, it is still
unclear whether patients with heart failure should be
treated immediately with more powerful assist devices
and in which patients further therapy is useless. Since
1989 we used, in a consecutive series of patients with
postcardiotomy left ventricular failure, the Hemopump
cardiac assist system (Medtronic, Minneapolis, Minn)
as the first-choice assist device in patients unsuitable
for transplantation because of their age or comorbidity.
We analyzed our data to delineate the indications for
mechanical support in heart failure.
Methods
Left ventricular failure strategy. If a patient cannot be
weaned from extracorporeal circulation, reperfusion is
allowed for half an hour. In that period, an IABP is placed and
P ostcardiotomy heart failure is the most troublesomecondition in cardiac surgery. Patients unable to be
weaned or patients undergoing failure in the first hours
after surgery are generally treated with increased
inotropic support and use of an intra-aortic balloon
Objective: We sought to identify the indications of mechanical support in
postcardiotomy left ventricular failure in patients who are unable to undergo
transplantation.
Methods: From 1989 through 1997, 61 patients with postcardiotomy left ven-
tricular failure beyond intra-aortic balloon pumping were assisted with the
Hemopump cardiac assist system (Medtronic, Minneapolis, Minn). Their
mean age was 64 ± 8 years. Comorbidity was prevalent; 47% underwent car-
diac massage before pump support, and evolving myocardial infarction was
diagnosed in 43% before surgery. Multivariable logistic regression of data
known at the moment of pump insertion was performed to identify the risk
factors for mortality.
Results: Sixty-five percent of the patients were weaned from the device, but
only 30% were discharged home. Cardiac index evolution during the first
hours after pump insertion (P < .001) is the only independent predictor for
possibility to wean from the device in the multivariable analysis. Acute renal
failure is the only variable retained in the model for 90-day mortality.
Device-related complications were far more frequent with the femoral (54%)
than with the transthoracic (6%) cannula. Only 13% of the patients had
bleeding complications.
Conclusions: One third of the patients with postcardiotomy heart failure
refractory to use of the intra-aortic balloon pump can be saved with the use
of an endovascular axial flow pump. It is impossible to predict lethal out-
come on preoperative data alone. The early hemodynamic response to sup-
port seems to be related to functional recovery of the heart and subsequent
weaning from the device. (J Thorac Cardiovasc Surg 2000;120:393-400)
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medical therapy is optimized. Medical therapy comprises
optimal filling; inotropic support with dobutamine,
dopamine, and enoximone; and, in cases of vasodilation, nor-
epinephrine. A second weaning attempt is undertaken. If
signs of left ventricular failure are still obvious (ie, cardiac
index < 2 L · m–2 · min–1 or systolic blood pressure < 90 mm
Hg with increased left atrial pressures), the Hemopump
device is inserted.
In cases in which left ventricular failure becomes obvious
some hours after surgery in the intensive care unit, medical
therapy is optimized, and an IAPB is inserted as a measure of
intensive care. If hemodynamics again indicate a persistently
failing ventricle, the patient is taken back to the operating
room, and the Hemopump device is inserted.
The device. The Hemopump cardiac assist system is a
miniaturized rotary blood pump mounted on a catheter (Fig
1). The rotor is driven by an electric motor. The bedside-
installed console allows regulation of the pump speed from
17,000 to 26,000 rotations per minute. Once the cannula is
placed over the aortic valve, it sucks the blood out of the left
ventricle and expells it into the ascending aorta. Two cannu-
las were used in this series: a femoral device and a transtho-
racic device. Both are 8.1-mm wide, but the femoral cannula
has a longer inflow tip and is less performant (maximum flow
of 3.5 L/min for the femoral and 5.1 L/min for the transtho-
racic cannula). The nonpulsatile flow delivered by the
Hemopump device is continuously influenced by the under-
lying cardiac activity.3,4 The Hemopump console does not
display the actually delivered flow, but a performance indica-
tor shows the varying motor current. From 1989 through
1992, the femoral cannula was used. From the first of January
1993, we switched to the transthoracic cannula.
Patients. From 1989, the date of introduction of the
Hemopump device in our institution, through December
31, 1997, 12,163 patients underwent cardiac surgery. Three
hundred eighty-eight (3.2%) patients received an IABP in
the perioperative period, and 108 (0.9%) patients were sup-
ported with a more powerful assist device. If bridging to
heart transplantation was the first option, the patient was
assisted with a medium-term pulsatile assist device (either
Abiomed from Abiomed Cardiovascular, Inc, Danvers,
Mass, or Medos from Medos, Stollberg, Germany). The
Hemopump is a short-term assist device and was only con-
sidered in cases of isolated left ventricular failure, with the
intention of recovering the cardiac function. Patients with
clinical signs of right ventricular or biventricular failure
received a right or biventricular assist device other than the
Hemopump device (centrifugal pump, Abiomed, and
Medos). The assessment of right ventricular function was
based on hemodynamic status (central venous pressure,
pulmonary artery pressure, and cardiac output), on
echocardiographic assessment of the right ventricular con-
tractility, and on clinical background. Therefore, 61
patients received the Hemopump system for isolated left
ventricular failure in a postcardiotomy setting, with recov-
ery of the heart as the only possible outcome.
Table I summarizes the biographical data of these 61
patients with a mean age of 64 ± 7.9 years. Many of them
were operated on under emergency conditions. Almost half of
these patients (47%) underwent cardiopulmonary resuscita-
tion before the Hemopump insertion, and in 43% of them, the
diagnosis of evolving myocardial infarction was known at the
moment of Hemopump initiation.
Important comorbidity is present with predominantly vas-
cular pathology and diabetes. The comorbidity and age were
exclusion criteria for heart transplantation for each of these
patients.
Surgical technique. The femoral Hemopump device is
inserted through a cutdown of the femoral artery. Bleeding on
insertion is controled by means of a 12-mm Dacron graft
sutured to the artery. The cannula is introduced through the
graft and then passed across the aortic arch and the aortic
valve under fluoroscopic guidance.
The transthoracic Hemopump device is inserted through a
graft sutured onto the ascending aorta. The cannula is passed
over the aortic valve under direct palpation of the ascending
aorta. The position of the cannula is confirmed by means of
transthoracic echocardiography. Occluding plugs around the
drive cable prevent blood loss through the graft once the can-
nula is in place. Tying one plug close to the ascending aorta
secures the position of the cannula and prevents displace-
ment.
Hemopump assist systems are inserted without extracorpo-
real circulation, with the exception of the patients unwean-
able from bypass. The transthoracic drive cable is positioned
with a smooth curve in the right pleural space and leaves the
chest through the caudal end of the sternotomy.
Removal of the transthoracic device requires resternotomy.
The graft is occluded as low as possible and sutured. 
Patient management. Inotropic support is stopped as soon
as possible. Vasopressors are continued in cases of vasodila-
tion. Hemodynamic goals are a mean aortic blood pressure of
70 mm Hg, with left atrial and right atrial pressures of 10 to
15 mm Hg. Filling volume is primarily triggered by the right
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Fig 1. The Hemopump cardiac assist system is a miniaturized
axial rotary blood pump. There were two cannulas in clinical
use: the long femoral type and the short transthoracic type.
Both are 8.1 mm wide.
atrial pressure because the right ventricular function is con-
sidered to be the limiting factor. Cardiac output by the ther-
modilution method indicates right ventricular output and
reflects the sum of both Hemopump and left ventricular out-
put. Besides the hemodynamic status and clinical signs, plas-
ma lactate levels are monitored to estimate peripheral organ
perfusion. In cases in which an IABP is present, we leave it
in place because we assume a beneficial effect to myocardial
blood flow.5
All patients remain sedated and mechanically ventilated
during Hemopump support. 
Once the drainage through the chest tubes indicates a dry
surgical field, we start a continuous heparin infusion to obtain
activated clotting time between 180 and 200 seconds.
The antibiotic routine consists of 3 × 2 g of a second-gen-
eration cephalosporin the day of surgery. Additional antibiot-
ic therapy is only initiated on guidance of clinical signs of
infection.
When recovery of the heart becomes obvious (by increas-
ing pulsatility of the arterial blood pressure), we wean the
patient gradually over several days by reducing the pump
speed. Transesophageal echocardiography is performed on
indication (like clinical suspicion of cardiac tamponade). On
the last day, with minimal Hemopump support, trans-
esophageal echocardiography is performed to judge myocar-
dial contractility and to plan the pump removal.
Statistical analysis. Continuous data are presented as
means and SD. Paired data are analyzed with the paired
Student t test. A Kaplan-Meier life-table curve was con-
structed with the statistical software package Statistica
(StatSoft Inc, Tulsa, Okla). Because mortality occurred in a
rather short period of time, a logistic regression analysis was
performed to predict 90-day mortality.
Simple logistic regression and multivariable logistic regres-
sion (SAS; SAS Institute Inc, Cary, NC) were performed to
analyze the influence of different clinical variables on the pos-
sibility of weaning the patients from the pump and on 90-day
mortality. The following variables known by the surgeon at
the time of urgent surgery, existing largely of crude historical
and hemodynamic data, were considered: age; weight; length;
the need for cardiopulmonary rescucitation before surgery; the
duration of shock before surgery (ie, shock is a cardiac index
<2 L· m–2 · min–1 or systolic pressure < 90 mm Hg with ele-
vated filling pressures); cardiac index before surgery; mean
blood pressure before surgery; left atrial pressure before
surgery; peripheral vascular disease; diabetes; chronic renal
failure (creatinine >2.5 mg/dL or hemodialysis); acute renal
failure (no urine output in the last hour); chronic obstructive
lung disease; redo surgery; left ventricular hypertrophy;
known severe reduction of ventricular ejection fraction; and
evolving acute myocardial infarction at the moment of
surgery. Furthermore, additional information gained by the
immediate hemodynamic response to the pump insertion were
also considered. These variables are cardiac index in the first
6 hours after insertion of the device, mean arterial blood pres-
sure in the first 6 hours after insertion of the device, and left
atrial pressure in the first 6 hours after insertion of the device.
The variables for which more than 25% of the data were miss-
ing were not allowed into the multivariable model.
Results
Weaning from the device. Immediate hemodynam-
ic recovery was obvious, with a significant increase in
cardiac index (from 1.8 ± 0.7 to 3.3 ± 0.8 L · m–2 ·
min–1; P < .0001) and mean arterial blood pressure
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Table I.  Biographic data of the patients supported with the Hemopump device (n = 61)
No. Observations % Mean ± SD
Age (y) 61 64 ± 8.0
Male sex 61 45 74
CPR before assist device 61 29 47
Acute myocardial infarction 60 27 45
Left ventricular hypertrophy 59 19 32
Acute renal failure 60 20 33
Peripheral vascular disease 59 16 27
Diabetes 59 13 22
Chronic obstructive pulmonary disease 60 4 7
Chronic renal failure 60 3 5
Duration of shock (h) 58 Median, 1 (25%-75%: 0.25-2.3)
Weight (kg) 52 73 ± 0.8
Length (cm) 52 169 ± 0.4
Cardiac index before assist device (L · m–2 · min–1) 39 1.8 ± 0.8
Mean blood pressure before assist device (mm Hg) 41 54 ± 12
Left atrial pressure before assist device (mm Hg) 35 19 ± 5
Cardiac index after assist device (L · m–2 · min–1) 47 3.3 ± 0.9
Mean blood pressure after assist device (mm Hg) 53 7.5 ± 4
Left atrial pressure after assist device (mm Hg) 51 10 ± 3
CPR, Cardiopulmonary resuscitation.
(from 54 ± 12 to 74 ± 14 mm Hg; P < .0001) and a
decrease in left atrial pressure (from 19 ± 5 to 10 ± 3
mm Hg; P < .0001). Weaning from the device was pos-
sible in 39 (65%) of the patients. Weaning was intend-
ed within the first week (longest duration on the device
was 10 days). Twenty percent of the patients died the
very first day of support. In all these cases a technical
pump failure was excluded. Mode of death in these
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Fig 2. The relation (with 95% confidence limits) between cardiac index in the first 6 hours after Hemopump sup-
port and the possibility of weaning the patient from the device.
Table II.  Simple and multivariable logistic regression of risk factors indicating the possibility of weaning the
patient from the device
OR 95% CI P value
Univariate analysis weaning
Sex (female vs male) 1.336 0.396-4.510 >.3
Age 0.952 0.884-1.025 .17
Weight 0.924 0.855-0.999 .04
Length 0.969 0.894-1.049 >.3
CPR 1.111 0.389-3.177 >.3
Duration of shock 1.012 0.954-1.074 >.3
Cardiac index* 0.966 0.396-2.353 >.3
Arterial blood pressure* 1.023 0.968-1.081 >.3
Left atrial pressure* 1.000 0.860-1.163 >.3
Peripheral vascular disease 1.179 0.345-4.029 >.3
Diabetes 0.510 0.145-1.796 .30
Chronic renal failure 0.000 0.000-1.244 .07
Acute renal failure 0.135 0.040-0.448 <.001
Chronic pulmonary disease 1.667 0.162-17.100 >.3
Redo surgery 1.120 0.366-3.428 >.3
Left ventricular hypertrophy 0.54 0.172-1.701 .29
Poor ejection fraction 0.583 0.189-1.803 >.3
Acute myocardial infarction 0.85 0.293-2.465 >.3
Cardiac index (after) 5.861 1.881-18.264 <.001
Mean blood pressure (after) 1.056 1.004-1.110 .02
Left atrial pressure (after) 0.982 0.817-1.181 >.3
Multivariable model weaning
Cardiac index (after) 5.861 1.881-18.264 <.001
OR, Odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation before insertion of the device; after, hemodynamic values obtained in the first 6 hours
after insertion of the device.
*Variable that is excluded from the multiple model because greater than 25% of the data are missing.
early failures was progressive vasodilation resistant to
high-dose vasopressors and insufficient organ perfu-
sion or discontinuation of therapy because of evidence
of brain death. Table II shows the clinical data known
in these emergency conditions and the level of their sig-
nificance to predict the possibility to wean the patient
from the device.
Body weight, acute renal failure, cardiac index, and
mean aortic blood pressure after the pump is started are
significant risk factors in a univariate analysis (Table
II). Of the 20 patients in acute renal failure (defined as
no urine output in the last hour), 6 had an immediate
improvement of the renal function (normal urine out-
put) once the mechanical support was initiated. Of
these 6 patients, 5 could be weaned from the device. On
the other hand, only 2 of the 14 patients without recu-
peration of the renal function could be weaned.
Once the device is inserted, additional information is
derived from the immediate hemodynamic response.
Cardiac index and mean arterial blood pressure after
use of the pump are significant predictors. However,
the multivariable logistic regression only retains car-
diac index after support as a significant factor. Fig 2
shows the relationship between cardiac index and the
possibility to wean the patient from the device. In our
series no patient with a cardiac index of less than 
2.5 L · m–2 · min–1 in the first hours after insertion of
the Hemopump device survived to be weaned.
Survival. The Kaplan-Meier survival curve (Fig 3)
indicates the drop in survival during the first week
before the patients were weaned. Although 65% of the
patients were weaned, only 30% were discharged home
alive. One patient died after discharge (mean follow-up
of 197 days). Death after weaning from the device was
due to late consequences of organ failure (eg, respira-
tory failure, sepsis, and hepatic failure) and low cardiac
output. Table III lists the clinical data known in the
operating room and their level of significance to predict
90-day mortality. Only acute renal failure and mean
arterial blood pressure after the support is commenced
are significantly related to 90-day mortality in a uni-
variate way. The mutivariable logistic regression
retains only acute renal failure.
Device-related complications. There is a striking
difference in occurrence of device-related complica-
tions between the earlier experiences with the femoral
device and the later experiences with the transthoracic
pump. Table IV summarizes the device-related compli-
cations. Problems of cannula introduction and drive
cable fracture were only seen with the femoral device.
Hemolysis (defined as plasma-free hemoglobin > 40
mg/dL) was only present in cases of pump blockage by
thrombus. Bleeding (defined as revision for bleeding or
tamponade or blood loss exceeding 1500 mL/12 hours)
occurred in 13% of the patients. We registered clinical
signs of embolic phenomena in none of these patients.
However, no specific investigation was performed to
exclude the occurrence of emboli.
Discussion
In 1965, Spencer and colleagues6 reported the first
successful use of ventricular support in patients with
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 2
Meyns et al 397
Fig 3. Kaplan-Meier survival curve of 61 patients with postcardiotomy heart failure supported by the Hemopump
device; the number of patients at risk is indicated above the horizontal axis. The assist device was in all cases
removed before day 10. Weaning was possible in 65% of the patients, and only 30% were discharged home. One
patient died after discharge.
postcardiotomy cardiac failure. Since then, the clinical
applications of ventricular assist devices have grown,
and several types of devices have been developed.
Reports of the use of these devices to support postcar-
diotomy heart failure show a hospital survival of 20%
to 30%.7-12 In earlier reports duration of support, older
age, and the presence of acute renal failure were
reported to be predictive for hospital mortality.8,12-14
However, later studies could not confirm these find-
ings.10 Regardless, the type of device used, bleeding,
and thromboembolic phenomena were the most fre-
quent complications.9,12 Therefore, the implantation of
an assist device remains a major surgical intervention
not likely to be done on a prophylactic basis. In clini-
cal practice an assist device is only used if all other
options have failed. However, several studies showed
that mechanical support reduces myocardial oxygen
consumption and infarct size and enhances myocardial
recovery after stunning.15-17 Exact knowledge of pre-
dictors for survival with and without assist devices is
therefore crucial. Baldwin and colleagues2 identified
complete heart block, female sex, advanced age, and
preoperative blood urea nitrogen as predictive parame-
ters for mortality in a group of 322 patients supported
with an IABP. We accepted the common principle that
whoever failed to do well with the IABP should
receive a ventricular assist device. In our consecutive
series of 61 patients treated with the same left ventric-
ular assist device (the Hemopump assist system), we
tried to identify the preoperative risk factors for sur-
vival. The factors that were shown to be significant
398 Meyns et al The Journal of Thoracic and
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Table III.  Simple and multivariable logistic regression of risk factors for 90-day mortality
OR 95% CI P value
Univariate analysis mortality
Sex (female vs male) 0.606 0.181-2.030 >.3
Age 1.067 0.994-1.145 .06
Weight 1.072 0.995-1.155 .05
Length 1.045 0.962-1.137 .29
CPR 0.574 0.188-1.781 >.3
Duration of shock 1.021 0.946-1.101 >.3
Cardiac index* 0.756 0.294-1.944 >.3
Arterial blood pressure* 0.954 0.898-1.014 .11
Left atrial pressure* 1.138 0.963-1.344 .11
Peripheral vascular disease 2.321 0.571-9.445 .22
Diabetes 1.613 0.386-6.739 >.3
Chronic renal failure +∞ 0.176-+∞ .54
Acute renal failure 6.000 1.221-29.480 .01
Chronic pulmonary disease 1.308 0.127-13.491 >.3
Redo surgery 0.786 0.250-2.468 >.3
Left ventricular hypertrophy 1.4 0.414-4.737 >.3
Poor ejection fraction 0.933 0.304-2.869 >.3
Acute myocardial infarction 2 0.632-6.327 .23
Cardiac index (after) 0.474 0.218-1.032 .05
Mean blood pressure (after) 0.949 0.905-0.994 .02
Left atrial pressure (after) 0.975 0.807-1.178 >.3
Multivariable model mortality
Acute renal failure 6.000 1.221-29.480 .01
OR, Odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation before the insertion of the device; after, hemodynamic values obtained in the first 6
hours after insertion of the device; ∞, infinity.
*Variable that is excluded from the multiple model because greater than 25% of the data are missing.




Cannula introduction (%) 3 (23) 0 (0)
Cannula displacement (%) 4 (31) 1 (2)
Thrombosed rotor (%) 1 (8) 2 (4)
Drive cable fracture (%) 1 (8) 0 (0)
Hemolysis (%) 3 (23) 2 (4)
Intervention required (%) 7 (54) 3 (6)
Bleeding (%) 8 (13)
Embolic phenomena (%) 0 (0)
Hemolysis is defined as a free plasma hemoglobin level of greater than 40
mg/dL. Bleeding is defined as revision for bleeding or tamponade or blood
loss greater than 1500 mL/12 hours. HP21, Femoral cannula; HP31, transtho-
racic cannula.
were less related to the patients’ general state but more
an expression of the degree of organ failure that took
place. The presence of acute renal failure is the only
preoperative variable associated with 90-day mortality
in the multivariable analysis. Second, the immediate
hemodynamic recovery of the patient is significantly
related to the possibility of weaning the patient. The
cardiac index in the first hours after initiation of the
device is the only significant predictor of the possibil-
ity to wean the patient from the device in the multi-
variable logistic regression. All patients with a cardiac
index under 2.5 L ·m–2 · min–1 within the first hours of
support died in the first days. The inability to improve
the hemodynamic state in these patients is probably
based on the deep cardiogenic shock these patients had
undergone before the pump was started. A general loss
of vasotonus that is resistant to vasopressors is often
the way this is expressed. The therapy in these patients
was definitely insufficient or inappropriate. The infor-
mation of the preoperative risk factors (acute renal
failure) and the response to the initiation of mechani-
cal support allows earlier decision making. This find-
ing has brought us to define the clinical pathways of
patients on an assist device in the operating room. If
they do not meet the criteria of hemodynamic response
within the first hours after the pump is placed, we
decide immediately on further actions. This can lead to
the use of biventricular support, the redirection of the
patient as a bridge to transplantation, or the defiance of
further invasive therapy. Not only the state of shock
but also the myocardial possibility of recovery, as well
as the general clinical state of the patient, are consid-
ered.
Although the analysis showed that the patients’
degree of shock is the major predictor of survival, this
only helps clinical decisions in patients who do not
immediately respond to mechanical support. The
known preoperative variables are or are related to the
patient’s general state (eg, age and vascular disease),
the myocardial potential for recovery (eg, poor ejection
fraction and acute myocardial infarction), or the degree
of shock (eg, acute renal failure and hemodynamic
data). Unfortunately, the overwhelming effect of the
latter category interferes with all other variables in this
specific patient group of postcardiotomy heart failure,
with recovery as the only outcome.10 In this series as
well, mechanical support was only initiated when all
other therapy failed. This has led to a selection of
patients with a high proportion of patients in clear
shock (47% were in cardiopulmonary resuscitation).
The true value of the variables from the other cate-
gories will only be discovered when shock is less
prevalent. This entails an earlier initiation of mechani-
cal support. The earlier initiation of mechanical sup-
port, however, is only justifiable if the side effects of
the device itself do not increase the risk for the patients.
With this miniaturized microaxial blood pump, this
evolution toward prophylactic use is possible.
We found an extremely low rate of bleeding compli-
cations (13%). In our experience and that of others12
with other assist devices, the incidence of bleeding is
reported to be as high as 50%. Clearly, the simplicity of
the device without the need for inflow and outflow can-
nulas is the underlying cause. The device proved to be
simple to introduce and remove, with an acceptable
thromboembolic complication rate and, as mentioned,
an extremely low bleeding rate. Other groups have
reported similar experiences with the Hemopump as an
assist device.18-20 Unfortunately, this device is no
longer available for clinical use. Several teams are
working on the development of elegant rotary blood
pumps.21-23 We look forward to this evolving technolo-
gy and hope that the improved devices will also offer
the same elegance and efficiency of the Hemopump
system, such as increased durability. In that case the
search for the ideal indications of the least invasive
mechanical support can be continued.
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